Virax Biolabs Group (NASDAQ:VRAX) Raised to Hold at Zacks Research

Virax Biolabs Group (NASDAQ:VRAX) was upgraded by research analysts at Zacks Research to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

Several other equities analysts have also recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $1.00 target price (down from $3.00) on shares of Virax Biolabs Group in a report on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Virax Biolabs Group has an average rating of “Hold” and a consensus price target of $1.00.

Virax Biolabs Group Stock Down 1.0%

Shares of VRAX traded down $0.00 during mid-day trading on Tuesday, hitting $0.33. 16,259 shares of the company traded hands, compared to its average volume of 333,571. The stock has a 50-day moving average price of $0.42 and a two-hundred day moving average price of $0.62. Virax Biolabs Group has a 1 year low of $0.30 and a 1 year high of $2.33.

Virax Biolabs Group (NASDAQ:VRAX) last announced its earnings results on Tuesday, December 2nd. The company reported ($0.27) earnings per share for the quarter. The business had revenue of $0.00 million for the quarter.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.